公开(公告)号：US20210388382A1

公开(公告)日：2021-12-16

申请号：US17053733

申请日：2019-05-08

Applicant: Neuracle Science Co., Ltd. ,  Neuracle Genetics

Inventor： Jong-Mook KIM ,  Dong Sik KIM ,  Juwon SHIM ,  Soon-gu KWON

IPC: C12N15/86 ,  C07K16/24

Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

公开(公告)号：US20220010332A1

公开(公告)日：2022-01-13

申请号：US17365884

申请日：2021-07-01

Applicant: NEURACLE GENETICS INC.

Inventor： Hoon Young KONG ,  Jong-Mook KIM ,  Jee Yong KIM ,  Sunhwa SHIN ,  Kyungwon LEE ,  Joo Seok HAN

IPC: C12N15/85 ,  C12N15/113

Abstract: Novel intron fragments are provided. The intron fragments can increase gene expression to levels equal to or higher than those achieved by the full-length intron while maintaining their ability to increase gene expression even when combined with various types of promoters and splicing donors. Particularly, the intron fragments enable loading of larger transgenes when used in genetic information delivery systems whose size is limited, for example, adeno-associated viruses (AAVs) and rhabdoviruses. Therefore, the use of the intron fragments is expected to extend the range of therapeutic genes.

公开(公告)号：US20250163455A1

公开(公告)日：2025-05-22

申请号：US18945052

申请日：2024-11-12

Applicant: NEURACLE GENETICS INC.

Inventor： Hoon Young KONG ,  Jong-Mook KIM ,  Jee Yong KIM ,  Sunhwa SHIN ,  Kyungwon LEE ,  Joo Seok HAN

IPC: C12N15/85 ,  C12N15/113 ,  C12N15/86

Abstract: Novel intron fragments are provided. The intron fragments can increase gene expression to levels equal to or higher than those achieved by the full-length intron while maintaining their ability to increase gene expression even when combined with various types of promoters and splicing donors. Particularly, the intron fragments enable loading of larger transgenes when used in genetic information delivery systems whose size is limited, for example, adeno-associated viruses (AAVs) and rhabdoviruses. Therefore, the use of the intron fragments is expected to extend the range of therapeutic genes.